Bone fractures in patients using tapentadol or oxycodone: an exploratory US claims database study.
Bart J MorlionCésar MargaritImane WildRavi KarraHiltrud LiedgensMelanie SohnsGabriele FincoPublished in: Pain management (2020)
Aim: To explore fracture outcomes with tapentadol or oxycodone, two opioids with differing mechanisms of action. Materials & methods: Retrospective cohort pilot study, using MarketScan® Commercial and Medicare Supplemental claims databases, on patients with postoperative pain, back pain, or osteoarthritis and ≥1 claim for tapentadol (n = 16,457), oxycodone (n = 1,356,920), or both (n = 15,893) between June 2009 and December 2015. Results: During 266,826 and 9,007,889 days of tapentadol and oxycodone treatment, patients evidenced 1080 and 72,275 fractures, respectively. Fracture rates per treatment-year were 1.512 for tapentadol and 3.013 for oxycodone. Conclusion: Examination of administrative claims has inherent limitations, but this exploratory analysis indicates a lower fracture rate with tapentadol than oxycodone in the analyzed dataset, which needs confirmation by further clinical trials.
Keyphrases
- end stage renal disease
- clinical trial
- newly diagnosed
- chronic kidney disease
- ejection fraction
- health insurance
- peritoneal dialysis
- prognostic factors
- postoperative pain
- emergency department
- rheumatoid arthritis
- healthcare
- randomized controlled trial
- chronic pain
- metabolic syndrome
- type diabetes
- knee osteoarthritis
- bone mineral density
- skeletal muscle
- patient reported
- machine learning
- insulin resistance
- postmenopausal women
- replacement therapy